Abstract:Background: Elevated lipoprotein (Lp(a)) levels are associated with increased risk of atherosclerotic processes and cardiovascular events in adults. The amount of Lp(a) is mainly genetically determined. Therefore, it is important to identify individuals with elevated Lp(a) as early as possible, particularly if other cardiovascular risk factors are present. The purpose of the study was to investigate whether, in a population of children and adolescents already followed for the presence of one or more cardiovascular risk factors (elevated blood pressure (BP), and/or excess body weight, and/or dyslipidemia), the measurement of Lp(a) can be useful for better stratifying their risk profile. Methods: In a sample of 195 children and adolescents, height, body weight, waist circumference and systolic (SBP) and diastolic (DBP) BP were measured. Body Mass Index (BMI) and SBP and DBP z-scores were calculated. Plasma Lp(a), total cholesterol, high-density lipoprotein (HDL), triglycerides, glucose, insulin, uric acid and creatinine were assessed. Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald formula. High Lp(a) was defined as ≥ 75 nmol/L and high LDL cholesterol as ≥ 3.37 mmol/L. Results: Our sample of children and adolescents (54.4% males, mean age 11.5 years) had median LDL cholesterol and Lp(a) values equal to 2.54 (interquartile range, IQR: 2.07-3.06) mmol/L and 22 (IQR: 7.8-68.6) nmol/L respectively. 13.8% of children had LDL cholesterol ≥ 3.37 mmol/L and 22.6 Lp(a) values ≥ 75 nmol/L. Lp(a) values were higher in children of normal weight than in those with excess weight (p = 0.007), but the difference disappeared if normal weight children referred for dyslipidemia only were excluded from the analysis (p = 0.210). 69.4% of children had normal Lp(a) and LDL cholesterol values and only 6.2% showed both elevated Lp(a) and LDL cholesterol levels. However, 16.6% of the sample, despite having normal LDL cholesterol, had elevated Lp(a) values. Multivariable analyses showed a significant association of LDL cholesterol both with Lp(a) values, and with the presence of elevated Lp(a) levels. For each mmol/L increase in LDL cholesterol the risk of having an elevated Lp(a) value increased by 73%. There was an inverse correlation between BMI z-score and Lp(a). Neither BP z-scores, nor other biochemical parameters were associated with Lp(a). Conclusions: In our population more than one out of five children had elevated Lp(a) values, and in about 17% of children elevated Lp(a) values were present in the absence of increased LDL cholesterol. Our results suggest that Lp(a) measurement can be useful to better define the cardiovascular risk profile in children and adolescents already followed for the presence of other cardiovascular risk factors such as elevated BP, excess body weight and high LDL cholesterol.

Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children.

The level of native and oxidized lipoprotein(a) in children with nephrotic syndrome.

[Value of Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1) and LOX-1 Mrna in Peripheral Mononuclear Cells in Early Diagnosis of Acute Coronary Syndrome].

[Correlation of Autoantibodies Against Oxidized Low Density Lipoprotein and Its Immune Complex with Coronary Artery Disease]

The level of plasma oxidized low-density lipoprotein and its immune complex in children with nephrotic syndrome

Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes.

Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL.

Is lipoprotein(a) measurement important for cardiovascular risk stratification in children and adolescents?

Elevated Serum Β2-Gpi-lp(a) Complexes Levels in Children with Nephrotic Syndrome

Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease.

Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results from the Bruneck Study

Native, Oxidized Lipoprotein(a) and Lipoprotein(a) Immune Complex in Patients with Active and Inactive Rheumatoid Arthritis: Plasma Concentrations and Relationship to Inflammation.

[Clinical Significance of Oxidized Low-Density Lipoprotein Antibody in Antiphospholipid Syndrome].

Lipoprotein (a) and its immune complexes in dyslipidemic subjects.

Development Of New Enzyme-Linked Immunosorbent Assay For Oxidized Lipoprotein(A) By Using Purified Human Oxidized Lipoprotein(A) Autoantibodies As Capture Antibody

Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease

Lipoprotein (a):A Vital Member of Blood Lipid Items

[Distribution and Influencing Factors of Lipoprotein (a) Levels in Non-Arteriosclerotic Cardiovascular Disease Population in China].

Lipoprotein(a) Is Markedly More Atherogenic Than LDL

The synergistic mechanisms of oxidized phospholipids and lipoprotein-associated phospholipase A2 associated with Lp ( a ) in promoting atherosclerosis

Lipoprotein(a) serum concentrations in children in relation to body mass index, age and sex